Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP080
MIFTS: 51

Hypogonadism

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypogonadism

About this section

MalaCards integrated aliases for Hypogonadism:

Name: Hypogonadism 12 76 29 55 44 15 73

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1924
MeSH 44 D007006
NCIt 50 C9227
SNOMED-CT 68 48130008
UMLS 73 C0020619
Sources

Summaries for Hypogonadism

About this section
Disease Ontology : 12 A gonadal disease that is characterized by diminished functional activity of the gonads.

MalaCards based summary : Hypogonadism is related to hypogonadotropic hypogonadism 23 without anosmia and hypogonadotropic hypogonadism 7 with or without anosmia. An important gene associated with Hypogonadism is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Hypogonadism means diminished functional activity of the gonads—the testes or the ovaries —that may... more...

Sources

Related Diseases for Hypogonadism

About this section

Diseases related to Hypogonadism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 23 without anosmia 33.6 GNRH1 GNRHR LHB
2 hypogonadotropic hypogonadism 7 with or without anosmia 33.4 DUSP6 FGF17 GNRH1 GNRHR SPRY4
3 hypogonadotropism 31.5 GNRH1 GNRHR KISS1 KISS1R
4 anosmia 30.0 ANOS1 FGF17 FGFR1 PROKR2 SPRY4
5 infertility 29.5 FSHB GNRH1 LHB LHCGR
6 charge syndrome 29.3 ANOS1 CHD7 FGFR1 GNRHR PROK2 PROKR2
7 precocious puberty 29.1 GNRH1 KISS1 KISS1R LHCGR
8 amenorrhea 29.0 FSHB GNRH1 LHB LHCGR
9 central precocious puberty 28.8 GNRH1 KISS1 KISS1R
10 normosmic congenital hypogonadotropic hypogonadism 27.5 ANOS1 CHD7 DUSP6 FGF17 FGFR1 GNRH1
11 kallmann syndrome 27.1 ANOS1 CHD7 DUSP6 FGF17 FGFR1 GNRH1
12 hypogonadotropic hypogonadism 26.6 ANOS1 CHD7 DUSP6 FGF17 FGFR1 FSHB
13 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 12.2
14 ataxia - hypogonadism - choroidal dystrophy 12.2
15 hypogonadotropic hypogonadism 1 with or without anosmia 12.2
16 hypogonadotropic hypogonadism 10 with or without anosmia 12.2
17 hypogonadotropic hypogonadism 21 with or without anosmia 12.2
18 hypogonadotropic hypogonadism 8 with or without anosmia 12.2
19 hypogonadotropic hypogonadism 11 with or without anosmia 12.2
20 hypogonadotropic hypogonadism 12 with or without anosmia 12.2
21 hypogonadotropic hypogonadism 13 with or without anosmia 12.2
22 hypogonadotropic hypogonadism 15 with or without anosmia 12.2
23 hypogonadotropic hypogonadism 16 with or without anosmia 12.2
24 hypogonadotropic hypogonadism 20 with or without anosmia 12.2
25 hypogonadotropic hypogonadism 9 with or without anosmia 12.2
26 hypogonadotropic hypogonadism 14 with or without anosmia 12.2
27 hypogonadotropic hypogonadism 17 with or without anosmia 12.2
28 hypogonadotropic hypogonadism 19 with or without anosmia 12.2
29 hypogonadotropic hypogonadism 22 with or without anosmia 12.2
30 hypogonadotropic hypogonadism 3 with or without anosmia 12.2
31 hypogonadotropic hypogonadism 5 with or without anosmia 12.2
32 hypogonadotropic hypogonadism 18 with or without anosmia 12.2
33 hypogonadism, male 12.2
34 hypogonadotropic hypogonadism 4 with or without anosmia 12.1
35 hypogonadotropic hypogonadism 6 with or without anosmia 12.1
36 hypogonadotropic hypogonadism 2 with or without anosmia 12.1
37 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 12.1
38 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.1
39 hypogonadotropic hypogonadism 24 without anosmia 12.0
40 deafness-hypogonadism syndrome 12.0
41 moyamoya disease 4 with short stature, hypergonadotropic hypogonadism, and facial dysmorphism 12.0
42 hydrocephalus obesity hypogonadism 12.0
43 intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome 11.9
44 retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome 11.9
45 gordon holmes syndrome 11.9
46 hypogonadism-cataract syndrome 11.8
47 hypergonadotropic hypogonadism and partial alopecia 11.8
48 muscular dystrophy, congenital, with infantile cataract and hypogonadism 11.8
49 retinitis pigmentosa, deafness, mental retardation, and hypogonadism 11.8
50 moebius axonal neuropathy hypogonadism 11.8

Graphical network of the top 20 diseases related to Hypogonadism:



Diseases related to Hypogonadism
Sources

Symptoms & Phenotypes for Hypogonadism

About this section

GenomeRNAi Phenotypes related to Hypogonadism according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.72 FGFR1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.72 KISS1 KISS1R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.72 FGFR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.72 FGFR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.72 KISS1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.72 KISS1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 KISS1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 KISS1 KISS1R LHB FGFR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.72 FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.72 LHB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.72 KISS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.72 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.72 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 LHB
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.72 FGFR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.72 KISS1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.72 KISS1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.72 KISS1R
20 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.72 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.72 LHB

MGI Mouse Phenotypes related to Hypogonadism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 CHD7 FGFR1 FSHB GNRH1 GNRHR KISS1
2 growth/size/body region MP:0005378 10.03 CHD7 DUSP6 FGFR1 GNRH1 GNRHR KISS1
3 homeostasis/metabolism MP:0005376 10 NR0B1 PROKR2 TAC3 TACR3 CHD7 DUSP6
4 digestive/alimentary MP:0005381 9.97 CHD7 FGFR1 GNRH1 GNRHR KISS1 KISS1R
5 nervous system MP:0003631 9.7 GNRH1 KISS1 KISS1R LHCGR NSMF PROK2
6 reproductive system MP:0005389 9.47 NSMF PROKR2 TAC3 TACR3 CHD7 FGFR1
Sources

Drugs & Therapeutics for Hypogonadism

About this section

Drugs for Hypogonadism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
5
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 23994
6
Dihydrotachysterol Approved Phase 4,Phase 2,Phase 1 67-96-9 5281010 5311071
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-28-2 5757
8 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 979-32-8
9
Polyestradiol phosphate Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 28014-46-2
10
Dutasteride Approved, Investigational Phase 4,Phase 2,Phase 1 164656-23-9 152945 6918296
11
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-83-0 5994
12
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
13
Menotropins Approved Phase 4,Not Applicable 61489-71-2, 9002-68-0 5360545
14
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
15
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
17
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
18
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3 67-97-0 6221 5280795
19
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
20 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Not Applicable
21 Follicle Stimulating Hormone Phase 4,Phase 3,Phase 2,Not Applicable
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
30 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
31 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Vardenafil Dihydrochloride Phase 4
33 Vasodilator Agents Phase 4,Early Phase 1
34 Hypoglycemic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 insulin Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
36 Insulin, Globin Zinc Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
38 Contraceptive Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
39 Estradiol 17 beta-cypionate Phase 4,Phase 3,Not Applicable,Early Phase 1
40 Estradiol 3-benzoate Phase 4,Phase 3,Not Applicable,Early Phase 1
41 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
43 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
46 Mitogens Phase 4
47 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
48 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
49 Ergocalciferols Phase 4,Phase 3
50 decanoic acid Phase 4

Interventional clinical trials:

(show top 50) (show all 347)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
2 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
3 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
4 Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
5 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
6 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
7 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
8 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
9 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
10 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
11 Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
12 Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment Completed NCT02111434 Phase 4 Testosterone
13 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism Completed NCT01160341 Phase 4 Testosteron
14 Sequential Therapy for Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
15 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
16 The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
17 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
18 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
19 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
20 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
21 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
22 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
23 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
24 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
25 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
26 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
27 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
28 Effect of Testosterone Replacement on Insulin Resistance Completed NCT00487734 Phase 4 Placebo for testosterone gel
29 Testosterone Replacement in Diabetes With Vascular Disease (Version 2) Completed NCT00355537 Phase 4 Testosterone;0.9% saline
30 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
31 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
32 Testosterone Replacement in Metabolic Syndrome and Inflammation Completed NCT01123278 Phase 4 Testosterone;Placebo
33 Testosterone Replacement in Older Men and Atherosclerosis Progression Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
34 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
35 Subcutaneous vs. Intramuscular Testosterone Completed NCT03091348 Phase 4 Testosterone
36 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
37 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
38 FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women Completed NCT02674178 Phase 4
39 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
40 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Recruiting NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
41 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
42 Testosterone Therapy in Hypogonadal Men Treated With Opioids Recruiting NCT02433730 Phase 4 Testosterone;placebo
43 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4 Anastrazole
44 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
45 Periodontal Profile of Hypogonadic Men Recruiting NCT03176537 Phase 4 Testosterone gel;Placebos
46 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
47 TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY Recruiting NCT03325647 Phase 4 Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution;Placebo injectable saline
48 The Health Influences of Puberty (HIP) Study Active, not recruiting NCT01775813 Phase 4 Metformin
49 Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment Active, not recruiting NCT02408445 Phase 4 testosterone cypionate 200mg/ml
50 NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) Terminated NCT01092858 Phase 4 Testosterone Undeconate (Nebido, BAY86-5037);Placebo

Search NIH Clinical Center for Hypogonadism

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hypogonadism

Sources

Genetic Tests for Hypogonadism

About this section

Genetic tests related to Hypogonadism:

# Genetic test Affiliating Genes
1 Hypogonadism 29
Sources

Anatomical Context for Hypogonadism

About this section

MalaCards organs/tissues related to Hypogonadism:

41
Bone, Prostate, Testes, Pituitary, Ovary, Endothelial, Brain
Sources

Publications for Hypogonadism

About this section

Articles related to Hypogonadism:

(show top 50) (show all 1287)
# Title Authors Year
1
Predictive factors for pituitary response to pulsatile GnRH therapy in patients with congenital hypogonadotropic hypogonadism. ( 29516878 )
2018
2
The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization. ( 28960429 )
2018
3
Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. ( 29967236 )
2018
4
Klinefelter syndrome: more than hypogonadism. ( 29382506 )
2018
5
Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism. ( 29789996 )
2018
6
Symptomatic Androgen Deficiency Develops only When Both Total and Free Testosterone Decline in Obese Men Who may have Incident Biochemical Secondary Hypogonadism: Prospective Results from the EMAS. ( 29855071 )
2018
7
FGFR1 disruption identified by whole genome sequencing in a male with a complex chromosomal rearrangement and hypogonadotropic hypogonadism. ( 29160040 )
2018
8
Screening for Hypogonadism in Primary Healthcare: How to do this Effectively. ( 29365335 )
2018
9
Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism. ( 29430665 )
2018
10
MRI of ectopic posterior pituitary gland with dysgenesis of pituitary stalk in a patient with hypogonadotropic hypogonadism. ( 29887929 )
2018
11
Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. ( 29392618 )
2018
12
Downregulation of leptin receptor and kisspeptin/GPR54 in the murine hypothalamus contributes to male hypogonadism caused by high-fat diet-induced obesity. ( 29948931 )
2018
13
Sertraline Suppresses Testis and Adrenal Steroid Production and Steroidogenic Gene Expression While Increasing LH in Plasma of Male Rats Resulting in Compensatory Hypogonadism. ( 29850907 )
2018
14
Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency. ( 29367875 )
2018
15
Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. ( 29425664 )
2018
16
The CATCH checklist to investigate adult-onset hypogonadism. ( 29888533 )
2018
17
Chronic cholestasis is associated with hypogonadism and premature ovarian failure in adult rats (cholestasis causes ovarian hypogonadism). ( 29297778 )
2018
18
Hypogonadism: Therapeutic Risks, Benefits, and Outcomes. ( 29406064 )
2018
19
Re: Ibuprofen Alters Human Testicular Physiology to Produce a State of Compensated Hypogonadism. ( 29783563 )
2018
20
Metabolic Syndrome in Male Hypogonadism. ( 29895018 )
2018
21
Benefit of routine testicular examination: hypogonadism in a person with 47XYY. ( 29415365 )
2018
22
Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism. ( 29514896 )
2018
23
Hypogonadism in male thalassemia major patients: pathophysiology, diagnosis and treatment. ( 29451224 )
2018
24
Novel Therapy for Male Hypogonadism. ( 29886559 )
2018
25
The Metabolic Syndrome in Central Hypogonadotrophic Hypogonadism. ( 29895006 )
2018
26
Deficiency in GnRH receptor trafficking due to a novel homozygous mutation causes idiopathic hypogonadotropic hypogonadism in three prepubertal siblings. ( 29777911 )
2018
27
Metabolic patterns in insulin-resistant male hypogonadism. ( 29867095 )
2018
28
Infertility treatment strategy involving combined freeze-all embryos and single vitrified-warmed embryo transfer during hormonal replacement cycle for in vitro fertilization of women with hypogonadotropic hypogonadism. ( 29436143 )
2018
29
Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. ( 29396841 )
2018
30
DCC/NTN1 complex mutations in patients with congenital hypogonadotropic hypogonadism impair GnRH neuron development. ( 29202173 )
2018
31
GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. ( 29330225 )
2018
32
Metabolic patterns in insulin-sensitive male hypogonadism. ( 29844353 )
2018
33
Primary adrenal insufficiency due to hereditary apolipoprotein AI amyloidosis: endocrine involvement beyond hypogonadism. ( 29446975 )
2018
34
Aging-related compensated hypogonadism: Role of metabolomic analysis in physiopathological and therapeutic evaluation. ( 29920416 )
2018
35
Congenital Hypogonadotropic Hypogonadism and Constitutional Delay of Growth and Puberty Have Distinct Genetic Architectures. ( 29419413 )
2018
36
Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism. ( 29311296 )
2018
37
The safety of available treatments of male hypogonadism in organic and functional hypogonadism. ( 29334271 )
2018
38
Transition of Care from Childhood to Adulthood: Congenital Hypogonadotropic Hypogonadism. ( 29886503 )
2018
39
Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity. ( 29974886 )
2018
40
Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. ( 29145707 )
2018
41
Delayed puberty versus hypogonadism: a challenge for the pediatrician. ( 29969875 )
2018
42
Hypogonadotropic Hypogonadism in Men With Diabesity. ( 29934480 )
2018
43
Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. ( 29777228 )
2018
44
HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy. ( 28081039 )
2017
45
Hypogonadotropic Hypogonadism in Males with Glycogen Storage Disease Type 1. ( 28160246 )
2017
46
SOX2 nonsense mutation in a patient clinically diagnosed with non-syndromic hypogonadotropic hypogonadism. ( 28659543 )
2017
47
Successful pregnancy and live birth from a hypogonadotropic hypogonadism woman with low serum estradiol concentrations despite numerous oocyte maturations: a case report. ( 28931393 )
2017
48
Approaches to male hypogonadism in primary care. ( 28085783 )
2017
49
Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism. ( 28320476 )
2017
50
KLB, encoding I^-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. ( 28754744 )
2017
Sources

Variations for Hypogonadism

About this section
Sources

Expression for Hypogonadism

About this section
Search GEO for disease gene expression data for Hypogonadism.
Sources

Pathways for Hypogonadism

About this section

Pathways related to Hypogonadism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 13.73 ANOS1 DUSP6 FGF17 FGFR1 FSHB GNRH1
2
Peptide ligand-binding receptors 66
Show member pathways
 12.96 FSHB GNRH1 GNRHR KISS1 KISS1R LHB
3
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.68 FGF17 FGFR1 GNRH1 LHB
4
G alpha (s) signalling events 66
11.66 FSHB LHB LHCGR
5
Ovarian steroidogenesis 37
11.12 FSHB LHB LHCGR
6
Hormone ligand-binding receptors 66
10.14 FSHB GNRH1 GNRHR LHB LHCGR
Sources

GO Terms for Hypogonadism

About this section

Cellular components related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 ANOS1 FGF17 FGFR1 FSHB GNRH1 KISS1

Biological processes related to Hypogonadism according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.84 FGF17 FSHB GNRH1 LHB
2 male gonad development GO:0008584 9.7 LHB LHCGR NR0B1
3 female pregnancy GO:0007565 9.67 FSHB GNRH1 TAC3
4 fibroblast growth factor receptor signaling pathway GO:0008543 9.63 ANOS1 FGF17 FGFR1
5 peptide hormone processing GO:0016486 9.55 FSHB LHB
6 regulation of osteoclast differentiation GO:0045670 9.51 FSHB LHCGR
7 male sex determination GO:0030238 9.48 GNRH1 NR0B1
8 cellular response to gonadotropin stimulus GO:0071371 9.43 LHCGR NSMF
9 hormone-mediated signaling pathway GO:0009755 9.43 FSHB LHB LHCGR
10 tachykinin receptor signaling pathway GO:0007217 9.4 TAC3 TACR3
11 G-protein coupled receptor signaling pathway GO:0007186 9.36 FSHB GNRH1 GNRHR KISS1 KISS1R LHB
12 follicle-stimulating hormone signaling pathway GO:0042699 9.32 FSHB LHCGR
13 neuropeptide signaling pathway GO:0007218 9.26 KISS1R PROK2 PROKR2 TAC3
14 progesterone biosynthetic process GO:0006701 9.16 FSHB LHB
15 signal transduction GO:0007165 10.02 FGF17 FSHB GNRH1 GNRHR KISS1R LHB

Molecular functions related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 FSHB GNRH1 LHB
2 protein-hormone receptor activity GO:0016500 8.62 GNRHR LHCGR
Sources

Sources for Hypogonadism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....